Coeptis Therapeutics, Inc. (COEP)

NASDAQ: COEP · IEX Real-Time Price · USD
1.76
-0.02 (-1.12%)
Dec 6, 2022 2:20 PM EST - Market open
-1.12%
Market Cap 9.11M
Revenue (ttm) 75,000
Net Income (ttm) -54.70M
Shares Out 38.66M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,640
Open 2
Previous Close 1.78
Day's Range 1.6 - 1.86
52-Week Range 1.69 - 21.42
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About COEP

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38... [Read more]

Industry Biotechnology
Founded 2017
Employees 4
Stock Exchange NASDAQ
Ticker Symbol COEP
Full Company Profile

Financial Performance

In 2021, COEP's revenue was $75,000, an increase of 143.82% compared to the previous year's $30,761. Losses were -$13.45 million, 46.9% more than in 2020.

Financial Statements

News

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

Coeptis to collaborate with IQVIA, a global contract research organization, to identify target indications and initiate IND-enabling activities for SNAP-CAR WEXFORD, Pa. , Nov. 22, 2022 /PRNewswire/ -- ...

Other symbols: IQV
2 weeks ago - PRNewsWire

Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell

WEXFORD, Pa. , Nov. 15, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that...

3 weeks ago - PRNewsWire

Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast

WEXFORD, Pa. , Nov. 8, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that ...

4 weeks ago - PRNewsWire

Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments

New directors join Coeptis' Board following completion of merger with Bull Horn Holdings and advancement to Nasdaq WEXFORD, Pa. , Nov. 2, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ...

1 month ago - PRNewsWire

This SPAC is merging with an already-public company as sponsors get creative before time runs out

Many sponsors face challenges as they race the clock to find a target amid regulatory crackdown and waning enthusiasm.

5 months ago - CNBC

Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technol...

Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement ...

6 months ago - PRNewsWire

Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform

Coeptis Therapeutics Inc (OTC: COEP) has entered into a strategic agreement with Statera Biopharma Inc (NASDAQ: STAB) that gives Coeptis the right to acquire Statera'stoll-like receptor 5 (TLR5) agonist...

7 months ago - Benzinga

Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, fro...

Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients WEXFORD, ...

Other symbols: STAB
7 months ago - PRNewsWire

Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development

WEXFORD, Pa., Jan. 20, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announces the formatio...

10 months ago - PRNewsWire